Sanofi

News

After a phase 2 readout, Sanofi is charting a route to market for AATD therapy efdoralprin alfa, acquired as part of its $2.2bn takeover of Inhibrx.

News

Sanofi's new chief executive, Belén Garijo, will see her tenure at the company kick-started by a strong 2026 first quarter.

News

The FDA has extended its review of a new version of Sanofi's multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.

News

Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a "destruction in shareholder value."

News

Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.

News

The EU has approved UCB's Kygevvi for rare disease TK2d, and Sanofi's acute GvHD therapy Rezurock, in a pair of decisions announced this morning.